Edwards Lifesciences Corporation ( EW - Free Report ) is well-poised for growth in the coming quarters, backed by the strength of the Surgical Structural Heart portfolio. In the third quarter of 2023, the company achieved several important milestones in TMTT (Transcatheter Mitral and Tricuspid Therapies), advancing toward the vision to build a portfolio of therapies to transform the lives of mitral and tricuspid patients. Favorable solvency also bodes well for the stock.